Showing 16,301 - 16,320 results of 43,028 for search '(( 5 ((mean decrease) OR (point decrease)) ) OR ( 100 ((we decrease) OR (a decrease)) ))', query time: 1.21s Refine Results
  1. 16301
  2. 16302

    Modeling three-dimensional diffusion from a single cell. by Ernesto Cuevasanta (172281)

    Published 2012
    “…We interrogate how the concentration of total sulfide (H<sub>2</sub>S+HS<sup>−</sup>) changes as a function of time and distance from the source cell with or without surrounding cells. …”
  3. 16303
  4. 16304
  5. 16305

    STATc is a key regulator of the transcriptional response to hyperosmotic shock-0 by Jianbo Na (12352)

    Published 2011
    “…After starvation for 4 hours, untreated cells and cells treated for 5 min with 50, 100, 200 and 400 mM sorbitol were fixed with ice cold methanol, and then stained with a monoclonal antibody specific for actin, followed by the incubation with anti-mouse IgG antibody conjugated with Cy5. …”
  6. 16306
  7. 16307
  8. 16308
  9. 16309
  10. 16310
  11. 16311
  12. 16312

    Examination of mitochondrial function and cell viability in <i>PLA2G6</i>-KD cells. by Goichi Beck (818821)

    Published 2015
    “…(B) Expression levels of CCO are decreased in <i>PLA2G6</i>-KD cells compared with those of SH-SY5Y cells treated with negative control siRNA with statistical significance (*<i>p < 0</i>.…”
  13. 16313

    Data_Sheet_1_Exploring organizational aspects that promote health-related preventive behavior: using the example of work-related SARS-CoV-2 infection control measures in Germany, A... by Jana Soeder (19779150)

    Published 2024
    “…A total of 16 items constitute the attitude scores toward oICM (5-point Likert scale). Via mixed-effect model, aspects associated with employees’ attitudes toward oICM were explored. …”
  14. 16314

    Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  15. 16315

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  16. 16316

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  17. 16317

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  18. 16318

    Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
  19. 16319
  20. 16320

    A binding mode landscape for disordered protein interactions. by Attila Horvath (285787)

    Published 2020
    “…Context-dependent <b>disorder-to-order</b> binding is exemplified by the <b>polymorphic interactions</b> of the ribosomal S6 kinase 1 (RSK1, residues 697–703, <i>light blue dots</i>), which adopts different secondary structures upon binding to S100B, corresponding to autoinhibited and active forms (PDB:5csf, 5csi, 5csj [<a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007864#pcbi.1007864.ref023" target="_blank">23</a>]). …”